• Reported GAAP EPS of -$0.20 up 60.00% YoY • Reported revenue of $0.15M up 499.58% YoY • Dare Bioscience expects existing cash and cash equivalents to fund operating needs, including planned DARE to PLAY commercial launch activities, into Q4 2026, though 2026 revenue is uncertain.
Bullish
Dare Bioscience achieved significant revenue growth and a reduced net loss, while advancing its DARE-HPV clinical study and expecting Flora Sync LF5 commercial availability in June 2026.
Bearish
Dare Bioscience faces substantial doubt about its going concern ability due to uncertain revenue generation from new strategies and delays in accessing critical non-dilutive grant funding.